Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients
Clinical and Translational Oncology, 06/12/2012SanchezRovira P et al. –
The results show an effective regimen with acceptable tolerability. The data suggest that not only classical markers, but also survivin and pERK could be involved in the response to GAT, which may contribute to therapy individualisation in future study designs.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.